CREDENCE Shifts Our Thinking About SGLT2 Inhibitors CREDENCE Shifts Our Thinking About SGLT2 Inhibitors
The CREDENCE trial allows us to start thinking of SGLT2 inhibitors as drugs for preserving renal function, independent of other parameters, says Anne Peters.Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 14, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news
More DECLARE-TIMI: Robust Renal Effects of Dapagliflozin More DECLARE-TIMI: Robust Renal Effects of Dapagliflozin
A new analysis from the landmark trial with the diabetes drug dapagliflozin shows a large, robust effect on important kidney outcomes. Accumulating data support ' leading role for SGLT2 inhibitors, ' in diabetes.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 11, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
Fournier Gangrene Is Safety Concern With SGLT2 Inhibitors
MONDAY, May 13, 2019 -- Fournier gangrene (FG) is a safety concern for adults with diabetes receiving treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitors, according to a study published online May 7 in the Annals of Internal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 13, 2019 Category: Pharmaceuticals Source Type: news
Study warns of flesh-eating genital infection linked to diabetes drugs
A new study echoes a previous FDA warning about the link between Type 2 diabetes drugs known as SGLT2 inhibitors and the genital infection called Fournier gangrene. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 9, 2019 Category: Pharmaceuticals Source Type: news
SGLT2, Fournier Gangrene Link Is'Compelling'--What to Do? SGLT2, Fournier Gangrene Link Is'Compelling'--What to Do?
Fournier gangrene is an uncommon but unignorable adverse event associated with SGLT2 inhibitors. What does this mean for clinical practice?Medscape (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - May 8, 2019 Category: Internal Medicine Tags: Internal Medicine Commentary Source Type: news
Diabetes Drugs Carry Risk of Gangrene of Genitals
Popular diabetes drugs known as SGLT2 inhibitors are linked with an increased risk of developing a flesh-eating bacteria that attacks the genitals, a rare condition known as Fournier gangrene. (Source: WebMD Health)
Source: WebMD Health - May 8, 2019 Category: Consumer Health News Source Type: news
Fournier Gangrene Alarm: More Cases Linked to Diabetes Drugs Fournier Gangrene Alarm: More Cases Linked to Diabetes Drugs
Physicians prescribing SGLT2 inhibitors, a newer class of diabetes drugs, are advised to"have a high index of suspicion" about the potentially fatal complication.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 6, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
SGLT2 Inhibitors for Diabetes Linked to Rare'Flesh-Eating' Genital Infection
MONDAY, May 6, 2019 -- Say you have type 2 diabetes and you are taking a newer class of medications to treat your disease -- but one day you notice pain, redness and a foul odor in your genital area.
If this happens, new research suggests you need... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 6, 2019 Category: General Medicine Source Type: news
Novel therapies slow CKD progression in patients with diabetes
(ERA-EDTA) The recently published CREDENCE study showed that SGLT2 inhibitors can slow progression of chronic kidney disease (CKD) in diabetes patients in addition to the effects seen with RAAS blockade. Canagliflozin was associated with a 34% risk reduction of the renal end point. The SONAR study had shown that the selective endothelin A receptor antagonist, atrasentan, reduced the risk of renal events in a specially selected CKD cohort with diabetes to a similar extent (35%). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 26, 2019 Category: International Medicine & Public Health Source Type: news
CREDENCE Takes SGLT2 Inhibitors'to the Next Level'CREDENCE Takes SGLT2 Inhibitors'to the Next Level '
What are the clinical implications of the CREDENCE trial? Dr Harpreet Bajaj shares his perspective on this landmark study.Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 25, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology Expert Column Source Type: news
Less HF Hospitalization on Dapagliflozin in Diabetes at Any LVEF Less HF Hospitalization on Dapagliflozin in Diabetes at Any LVEF
Survivals gains were seen in DECLARE-TIMI 58 only in those with low ejection fractions. Preliminary, but it suggests an SGLT2 inhibitor benefit in a range of people with diabetes and heart failure.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 4, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
Diabetes and Kidney Complications Garnering Attention at ISN Diabetes and Kidney Complications Garnering Attention at ISN
First results indicating that an SGLT2 inhibitor could improve outcomes for patients with diabetes and chronic kidney disease will be presented at the upcoming nephrology world congress.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 26, 2019 Category: Consumer Health News Tags: Nephrology News Source Type: news
Low EF Heart Failure Benefits Most From SGLT2 Diabetes Drug
(MedPage Today) -- DECLARE substudy doesn ' t leave HFpEF entirely out, though (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 20, 2019 Category: Cardiology Source Type: news
EU Panel OKs Sotagliflozin for Some With Type 1 Diabetes EU Panel OKs Sotagliflozin for Some With Type 1 Diabetes
The decision includes a list of requirements for use of the SGLT1/ SGLT2 inhibitor in select patients to minimize DKA risk. The EU approval will be the first worldwide for sotagliflozin.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 1, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
SGLT2 Inhibitors to Prevent HF: Time to Get More Proactive? SGLT2 Inhibitors to Prevent HF: Time to Get More Proactive?
Drs Pi ñ a and Butler discuss the accumulating ' consistent ' data regarding SGLT2 inhibitors for prevention of heart failure in patients with diabetes.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 4, 2019 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
